100
Participants
Start Date
October 10, 2018
Primary Completion Date
September 30, 2026
Study Completion Date
December 31, 2026
subcutaneous heparin anticoagulation
The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
RECRUITING
Baylor Scott & White Health research institute, Dallas
Lead Sponsor
Baylor Research Institute
OTHER